ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026
Recent trends of incidence and mortality of cutaneous lymphomas in Germany.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary cutaneous lymphomas (PCL) are primarily composed of cutaneous T-cell lymphomas (CTCL), followed by cutaneous B-cell lymphomas (CBCL). This study aimed to assess the incidence and survival rates of PCL in Germany.
methodsWe analyzed data from the North Rhine-Westphalia Cancer Registry (2008-2021), which covers a population of 18 million. Age-standardized incidence rates and relative survival were calculated.
resultsThe analysis included 3,853 patients with newly diagnosed PCL. Of these, 69.5% were CTCL, and 24.9% were CBCL. The age-standardized incidence of PCL was 10.8 per million person-years. The incidence of both CTCL and CBCL increased over time. PCL cases were also identified in children. The overall five-year relative survival for PCL was 89% (95% CI: 87-92%), with CTCL patients having a survival rate of 91% (95% CI: 88-94%) and CBCL patients of 86% (95% CI: 81-91%). Among patients with Sézary syndrome, the five-year relative survival was 53% (95%: CI:29-77%).
conclusionsThis study represents the largest population-based analysis of PCL in Germany, including both adults and children. The incidence of PCL was higher than previously reported. Additionally, we present the first survival data for PCL in Germany, revealing a notably higher survival probability for patients with Sézary syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.